An analysis of the current perspective and review regarding bone metastasis in colorectal adenocarcinoma

Budhi Ida Bagus; Hanis Setyono; Suwardi; Wibisono

doi:10.18203/2349-2902.isj20252704

Authors

Budhi Ida Bagus Department of Surgery, Sebelas Maret University, Indonesia
Hanis Setyono Department of Surgery, Sebelas Maret University, Indonesia
Suwardi Department of Surgery, Sebelas Maret University, Indonesia
Wibisono Department of Surgery, Sebelas Maret University, Indonesia

DOI:

https://doi.org/10.18203/2349-2902.isj20252704

Keywords:

Colorectal adenocarcinoma, Bone metastasis, Management

Abstract

In developed regions, colorectal cancer (CRC) is the third most common cause of cancer-related death, with 1.2 million new cases diagnosed annually worldwide. Six percent of all CRC metastases are bone metastases. Remarkably, 70% of patients develop distant metastases during follow-up, and 22% of patients show them at diagnosis. Bone metastases indicate a worsened oncological prognosis, even though they are rare. Six percent of all CRC metastases are bone metastases. Treating CRC that has spread to the bones can be difficult and frequently signals an advanced stage of the disease. Since the bone is frequently the site of metastasis for a variety of primary tumours, including breast, prostate, lung, thyroid, and kidney cancer, managing bone metastases is a crucial component of cancer care. In addition to reducing pain and complications, effective treatment of bone metastases can enhance patients' quality of life.

Metrics

Metrics Loading ...

References

Matías-García B, Mendoza-Moreno F, Díez-Alonso M, Ovejero-Merino E, Vera-Mansilla C, et al. Single metachronous bone metastasis following rectal adenocarcinoma: A case report. Med Int (Lond). 2024;4(1):6. DOI: https://doi.org/10.3892/mi.2024.130

Fornetti J, Welm AL, Stewart SA. Understanding the Bone in Cancer Metastasis. J Bone Miner Res. 2018;33(12):2099-113. DOI: https://doi.org/10.1002/jbmr.3618

Kobayashi Y, Shida D, Boku N, Yasui K, Nakamura Y, Kudose Y, et al. Prognostic factors of bone metastases from colorectal cancer in the era of targeted therapy. Dis Colon Rectum. 2023;66:401-9. DOI: https://doi.org/10.1097/DCR.0000000000002270

Ma CX, Guan X, Wei R, Wang S, Quan JC, Zhao ZX, et al. The distinction of clinicopathological characteristics, treatment strategy and outcome in colorectal cancer patients with synchronous vs. metachronous bone metastasis. Front Oncol. 2020;10:974. DOI: https://doi.org/10.3389/fonc.2020.00974

Zhenghong, Zihua Z, Guoweijian, Zhangning, Caiyunyun, Yingjiangshan, et al. Retrospective study of predictors of bone metastasis in colorectal cancer patients. J Bone Oncol. 2017;9:25-8. DOI: https://doi.org/10.1016/j.jbo.2017.10.003

Suresh Babu MC, Garg S, Lakshmaiah KC, Babu KG, Kumar RV, Loknatha D, et al. Colorectal cancer presenting as bone metastasis. J Cancer Res Ther. 2017;13:80-3. DOI: https://doi.org/10.4103/0973-1482.181177

Liu Z, Xu Y, Xu G, Baklaushev VP, Chekhonin VP, Peltzer K, et al. Nomogram for predicting overall survival in colorectal cancer with distant metastasis. BMC Gastroenterol. 2021;21(1):103. DOI: https://doi.org/10.1186/s12876-021-01692-x

Yin S, Zhai X, Li Y, Zeng R, Zhang D, Sun X, et al. Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation. Cancer Med. 2025;14(5):e70737.

Tang Z, Zhou G, Xu Y, Zhang Y. Survival analysis and prediction of early-onset colorectal cancer patients post-chemotherapy: an analysis based on the SEER database. Int J Colorectal Dis. 2025;40(1):74.

Nozue M, Oshiro Y, Kurata M, Seino K, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109-12. DOI: https://doi.org/10.3892/or.9.1.109

Chen Q, Li K, Rhodin KE, Deng Y, Lidsky ME, Luo S, et al. Development and internal validation of individualized prediction models of overall survival and 6-month mortality among patients with synchronous early-onset colorectal liver metastases. HPB (Oxford). 2024;26(11):1349-63. DOI: https://doi.org/10.1016/j.hpb.2024.07.413

Gao Y, De S, Brazil DP. The Role of GREMLIN1, a Bone Morphogenetic Protein Antagonist, in Cancer Stem Cell Regulation. Cells. 2025;14(8):578. DOI: https://doi.org/10.3390/cells14080578

Nakamura S, Fukui T, Suzuki S, Takeda H, Watanabe K, Yoshioka T. Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of KRAS-wildtype rectal cancer. Onco Targets Ther. 2017;10:1143-7. DOI: https://doi.org/10.2147/OTT.S129275

Popescu I, Dudău AM, Dima S, Herlea V, Croitoru VM, Dinu IM, et al. Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review. Medicina (Kaunas). 2024;60(5):696. DOI: https://doi.org/10.3390/medicina60050696

Zeeneldin A, Al-Dhaibani N, Saleh YM, Ismail AM, Alzibair Z, Moona MS, et al. Anorectal Cancer with Bone Marrow and Leptomeningeal Metastases. Case Rep Oncol Med. 2018;2018:9246139. DOI: https://doi.org/10.1155/2018/9246139

Lazzaroni M, Angelini F, Guglielmi R, Novizio R, Iadevaia A, Andreadi A, et al. Severe Hypercalcemia Following Pembrolizumab Therapy: A Case Report and A Literature Review. Endocr Metab Immune Disord Drug Targets. 2025. DOI: https://doi.org/10.2174/0118715303409910250725043347

Yin S, Zhai X, Li Y, Zeng R, Zhang D, Sun X, et al. Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation. Cancer Med. 2025;14(5):e70737. DOI: https://doi.org/10.1002/cam4.70737

Xiaobin C, Zhaojun X, Tao L, Tianzeng D, Xuemei H, Fan Z, et al. Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study. J Immunol Res. 2022;2022:3251051. DOI: https://doi.org/10.1155/2022/3251051

Tang Z, Zhou G, Xu Y, Zhang Y. Survival analysis and prediction of early-onset colorectal cancer patients post-chemotherapy: an analysis based on the SEER database. Int J Colorectal Dis. 2025;40(1):74. DOI: https://doi.org/10.1007/s00384-025-04853-6

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA. 2023;73(3):233-54. DOI: https://doi.org/10.3322/caac.21772

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91. DOI: https://doi.org/10.1136/gutjnl-2015-310912

Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7(3):262-74. DOI: https://doi.org/10.1016/S2468-1253(21)00426-X

Dwyer AJ, Murphy CC, Boland CR, Garcia R, Hampel H, Limburg P, et al. A summary of the fight colorectal cancer working meeting: exploring risk factors and etiology of sporadic early-age onset colorectal cancer. Gastroenterol. 2019;157(2):280-8. DOI: https://doi.org/10.1053/j.gastro.2019.04.049

Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology. 2020;158(2):341-53. DOI: https://doi.org/10.1053/j.gastro.2019.07.055

Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25(8):1128-39. DOI: https://doi.org/10.1038/modpathol.2012.61

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019;125(12):2002-10. DOI: https://doi.org/10.1002/cncr.31994

Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, et al. Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study. Int J Epidemiol. 2016;45(3):871-83. DOI: https://doi.org/10.1093/ije/dyv177

Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009;124(10):2406-15. DOI: https://doi.org/10.1002/ijc.24191

Chan GHJ, Chee CE. Making sense of adjuvant chemotherapy in colorectal cancer. J Gastrointestinal Oncol. 2019;10(6):1183-92. DOI: https://doi.org/10.21037/jgo.2019.06.03

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669-85. DOI: https://doi.org/10.1001/jama.2021.0106

Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023;9(1):21. DOI: https://doi.org/10.1038/s41572-023-00432-7

Kolarich A, George TJ Jr, Hughes SJ, Delitto D, Allegra CJ, Hall WA, et al. Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease. Cancer 2018;124(17):3510-9. DOI: https://doi.org/10.1002/cncr.31527

Eng C, Jácome AA, Agarwal R, Hayat MH, Byndloss MX, Holowatyj AN, et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022;23(3):e116-28. DOI: https://doi.org/10.1016/S1470-2045(21)00588-X

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-75. DOI: https://doi.org/10.1038/s41575-019-0126-x

Castro-Espin C, Agudo A. The role of diet in prognosis among cancer survivors: a systematic review and meta-analysis of dietary patterns and diet interventions. Nutrients. 2022;14(2):348. DOI: https://doi.org/10.3390/nu14020348

Okamoto K, Ozawa T, Nozawa H, Sasaki K, Murono K, Emoto S, et al. Prognosis of early-onset vs. late-onset stage II/III colorectal cancer patients with adjuvant chemotherapy: a multicenter propensity score matched study. Int J Clin Oncol. 2024;29(11):1721-9. DOI: https://doi.org/10.1007/s10147-024-02601-4

Coughlin SS. Social determinants of colorectal cancer risk, stage, and survival: a systematic review. Int J Colorectal Dis. 2020;35(6):985-95. DOI: https://doi.org/10.1007/s00384-020-03585-z

Vuik FER, Nieuwenburg SAV, Nagtegaal ID, Kuipers EJ, Spaander MCW. Clinicopathological characteristics of early onset colorectal cancer. Alimentary Pharmacol Therapeut. 2021;54(11-12):1463-71. DOI: https://doi.org/10.1111/apt.16638

Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, et al. Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients. Ann Oncol. 2018;29:v97. DOI: https://doi.org/10.1093/annonc/mdy150.014

Fernández-Ponce C, Geribaldi-Doldán N, Sánchez-Gomar I, Quiroz RN, Ibarra LA, Escorcia LG, et al. The role of glycosyltransferases in colorectal cancer. Int J Mol Sci. 2021;22(11):5822. DOI: https://doi.org/10.3390/ijms22115822

Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. 2019;35(6):294-305. DOI: https://doi.org/10.3393/ac.2019.11.13

Zhong M, Wu B. Zhongguo yi xue ke xue yuan xue bao. Acta Academ Medic Sinicae. 2021;43(6):980-5.